Hypersensitivity to ofloxacin and other quinolone derivatives. Tarivid is not indicated in children or adolescents in the growth phase and in pregnant or breastfeeding women, because its safety in such patients has not yet been sufficiently documented and, judging from animal experiments, the risk of damage to the cartilage of joints in the growing organisms cannot be altogether excluded.